Curapath Appoints Philippe Clavel as Chief Executive Officer

Curapath, a developer, manufacturer, and formulator of lipid- and polymer-based nanoparticles used in advanced therapeutic delivery technology, today announced the appointment of Philippe Clavel as Chief Executive Officer. Curapath is a portfolio company of Arcline Investment Management.

Philippe has previously held leadership positions in the pharmaceutical and biotechnology industries. Most recently, he served as the Vice President of the Pharmaceutical Solutions division of SEQENS, a global provider of active ingredients, pharmaceutical intermediates, and specialty ingredients. Previously, he held management positions at Sanofi. Philippe has a Ph.D. in organic chemistry from the Université de Bordeaux.

Arcline commented, “We are incredibly excited to welcome Philippe as Curapath’s CEO. His track record of building and growing businesses that address critical demands in the pharmaceutical and biotechnology sectors makes him the ideal leader for Curapath’s next phase of growth.”

Philippe said, “I am thrilled to join Curapath and partner with innovators to improve the efficacy and safety profiles of nanoparticle delivery systems for novel therapeutics. I look forward to working with the exceptional Curapath team to enable customers to bring urgently needed treatments to patients across multiple disease areas.”

About Curapath

Curapath, with over a decade of unwavering commitment, is dedicated to transforming lives through innovative therapies. With strong expertise in the development and manufacturing of polymers, lipid excipients, and optimized nanoparticle formulations, Curapath simplifies your non-viral gene therapy manufacturing process, offering seamless scalability for both small and large-scale cGMP manufacturing volumes. Having supported more than 50 therapeutic programs from preclinical to commercialization in advanced drug delivery formulations, Curapath is a proven partner to choose for unleashing innovative therapies and confidently navigating the journey from concept to impact on patients. For more information, please visit www.curapath.com.

The Latest from Curapath
Curapath & Certest Join Forces to Offer Next-Generation Lipid Nanoparticles (LNP) Formulations with Proprietary Excipients

VALENCIA & ZARAGOZA, SPAIN, 07 OCT 2024. Curapath, a leading innovator in the manufacturing of novel lipid and polymer excipients, nanoparticle formulations and innovative polymer conjugates,...

Curapath Strengthens Partnership in Breakthrough Genetic Medicine with Multiyear Development and Manufacturing Agreement

BOSTON and VALENCIA, Feb. 14, 2024 – Curapath, a leader in the development and custom manufacturing of polymer- and lipid-based delivery systems for advanced therapies, has...

Curapath Receives Accreditation as a GMP Investigational Drug Product Manufacturer from the Spanish Agency for Medicine and Health Products

Valencia, Spain and Boston, MA, January 26, 2023 – Curapath, a leader in the design, development, andcustom manufacturing of polyamino-acid- and lipid nanoparticle (LNP) delivery systems...